Sergio A Giralt

Summary

Affiliation: The University of Texas
Country: USA

Publications

  1. ncbi request reprint Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions
    Sergio Giralt
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 462, Houston, TX 77030, USA
    Curr Hematol Rep 4:200-7. 2005
  2. doi request reprint International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
    S Giralt
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 23:1904-12. 2009
  3. doi request reprint Advances in stem cell transplantation: making it better and safer
    Sergio Giralt
    Department of Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S293-5. 2009
  4. ncbi request reprint Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Sergio A Giralt
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
    Br J Haematol 137:461-7. 2007
  5. ncbi request reprint Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program
    Sergio Giralt
    The Nonmyeloablative Study Group, Center for International Blood and Marrow Transplant Research and the National Marrow Donor Program, Minneapolis, Minneapolis, USA
    Biol Blood Marrow Transplant 13:844-52. 2007
  6. ncbi request reprint Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions
    Sergio Giralt
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 462, Houston, TX 77030, USA
    Curr Hematol Rep 3:165-72. 2004
  7. doi request reprint Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    Yee Chung Cheng
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Hematol 90:627-34. 2009
  8. doi request reprint Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:1841-5. 2011
  9. ncbi request reprint Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1084-9. 2006
  10. doi request reprint Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction
    Muzaffar H Qazilbash
    Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:1265-70. 2009

Research Grants

Detail Information

Publications105 found, 100 shown here

  1. ncbi request reprint Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions
    Sergio Giralt
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 462, Houston, TX 77030, USA
    Curr Hematol Rep 4:200-7. 2005
    ..New agents being developed for MDS may have a potential impact on transplant outcomes. Therefore, design and implementation of clinical trials of transplant for MDS should be encouraged to improve the natural history of this disease...
  2. doi request reprint International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100)
    S Giralt
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Leukemia 23:1904-12. 2009
    ..The panel was asked to discuss a variety of issues regarding stem cell collection and transplantation in myeloma especially with the arrival of plerixafor. Herein, is a summary of their deliberations and conclusions...
  3. doi request reprint Advances in stem cell transplantation: making it better and safer
    Sergio Giralt
    Department of Stem Cell Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S293-5. 2009
    ..These trials should allow more patients with acute myeloid leukemia or myelodysplastic syndromes to achieve long and productive lives...
  4. ncbi request reprint Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia
    Sergio A Giralt
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77230, USA
    Br J Haematol 137:461-7. 2007
    ..Most patients now receive a trial of imatinib before proceeding to HCT...
  5. ncbi request reprint Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program
    Sergio Giralt
    The Nonmyeloablative Study Group, Center for International Blood and Marrow Transplant Research and the National Marrow Donor Program, Minneapolis, Minneapolis, USA
    Biol Blood Marrow Transplant 13:844-52. 2007
    ..However, only prospective trials will define the optimal role of this therapy in patients with hematologic malignancies. Therefore, URD transplantation with RIC should continue to be explored in the context of clinical trials...
  6. ncbi request reprint Bone marrow transplant in myelodysplastic syndromes: new technologies, same questions
    Sergio Giralt
    University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Box 462, Houston, TX 77030, USA
    Curr Hematol Rep 3:165-72. 2004
    ..New agents being developed for MDS may have a potential impact on transplant outcomes. Therefore, design and implementation of clinical trials of transplant for MDS should be encouraged to improve the natural history of this disease...
  7. doi request reprint Interleukin-2 and granulocyte-macrophage-colony-stimulating factor immunomodulation with high-dose chemotherapy and autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer
    Yee Chung Cheng
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Int J Hematol 90:627-34. 2009
    ..Estimated 3-year progression-free and overall survival rates were 31 and 57%. Our study suggested that the use of IL-2 and growth factors immunomodulation with HDC/AHST was feasible with comparable survival rates...
  8. doi request reprint Platelet recovery before allogeneic stem cell transplantation predicts posttransplantation outcomes in patients with acute myelogenous leukemia and myelodysplastic syndrome
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 17:1841-5. 2011
    ....
  9. ncbi request reprint Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 106:1084-9. 2006
    ..The outcomes of salvage autologous or allogeneic transplants were analyzed retrospectively in patients relapsing after an autograft...
  10. doi request reprint Outcome of allogeneic hematopoietic stem cell transplantation in patients with low left ventricular ejection fraction
    Muzaffar H Qazilbash
    Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:1265-70. 2009
    ..03). In conclusion, selected patients with a LVEF of < or =45% can safely receive allo-HCT without a significant increase in cardiac toxicity or NRM...
  11. doi request reprint Autologous hematopoietic stem cell transplantation may reverse renal failure in patients with multiple myeloma
    Gaurav C Parikh
    Department of Stem Cell Transplantation and Cellular Therapy, M D Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 15:812-6. 2009
    ..In this analysis, a melphalan (Mel) dose of 200 mg/m(2) was not associated with an increase in toxicity or nonrelapse (Mel) mortality (NRM)...
  12. doi request reprint Myeloablative reduced-toxicity i.v. busulfan-fludarabine and allogeneic hematopoietic stem cell transplant for patients with acute myeloid leukemia or myelodysplastic syndrome in the sixth through eighth decades of life
    Gheath Alatrash
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 17:1490-6. 2011
    ..Our results suggest that age alone should not be the primary reason for exclusion from receiving myeloablative reduced-toxicity conditioning with i.v. Bu-Flu preceding transplantation in patients with AML/MDS...
  13. doi request reprint Symptom burden after autologous stem cell transplantation for multiple myeloma
    Erica Campagnaro
    Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 112:1617-24. 2008
    ..Thorough assessment and understanding of symptoms and risk factors for symptom development after ASCT are logical first steps toward developing strategies aimed at reducing the symptom burden associated with this procedure...
  14. doi request reprint Durable responses after donor lymphocyte infusion for patients with residual multiple myeloma following non-myeloablative allogeneic stem cell transplant
    Amer M Beitinjaneh
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77054, USA
    Leuk Lymphoma 53:1525-9. 2012
    ..The role of DLI needs to be further explored in prospective clinical trials...
  15. ncbi request reprint Risk factors for relapse after complete remission with high-dose therapy for multiple myeloma
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation UT MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:1360-4. 2006
    ..We conclude that high tumor mass at diagnosis predicts a significantly shorter remission duration for myeloma patients undergoing autografting...
  16. ncbi request reprint Deletion of the short arm of chromosome 1 (del 1p) is a strong predictor of poor outcome in myeloma patients undergoing an autotransplant
    Muzaffar H Qazilbash
    Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:1066-72. 2007
    ..02 and .08, respectively). Deletion 1p is associated with a significantly shorter remission and survival in patients undergoing high-dose therapy and a single autologous transplant for myeloma...
  17. doi request reprint Hematopoietic progenitor cell collection in patients with chronic myelogenous leukemia in complete cytogenetic remission after imatinib mesylate therapy
    Qaiser Bashir
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 51:1478-84. 2010
    ..In conclusion, a significant number of CD34+ cells can be safely collected in patients with CML who are on imatinib therapy, but CD34+ cell yields improve when imatinib is temporarily withheld...
  18. doi request reprint High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Transplantation 88:1019-24. 2009
    ..Anti-HLA sensitization should be evaluated routinely in hematopoietic stem-cell transplantation with HLA mismatched donors...
  19. doi request reprint Disease staging with positron emission tomography or gallium scanning and use of rituximab predict outcome for patients with diffuse large B-cell lymphoma treated with autologous stem cell transplantation
    Amin M Alousi
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX, USA
    Br J Haematol 142:786-92. 2008
    ..We conclude that evidence of disease on PET/G scanning prior to transplantation is associated with an increased risk for relapse after ASCT. Transplantation regimens containing rituximab can reduce this risk, regardless of PET/G status...
  20. ncbi request reprint Results of a retrospective single institution analysis of targeted skeletal radiotherapy with (166)Holmium-DOTMP as conditioning regimen for autologous stem cell transplant for patients with multiple myeloma. Impact on transplant outcomes
    Anna V Christoforidou
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 13:543-9. 2007
    ....
  21. doi request reprint Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia
    Elias Jabbour
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Cancer 115:1899-905. 2009
    ..The authors hypothesized that low doses of the hypomethylating agent 5-azacitidine may maximize the graft-versus-leukemia effect and may be tolerated well after allogeneic transplantation (HSCT)...
  22. ncbi request reprint Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan
    Betul Oran
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 13:454-62. 2007
    ..Use of unrelated donors increased the risk of NRM only among patients with active disease. FM and HSCT elicited long-term disease control in a significant fraction of this high-risk cohort...
  23. doi request reprint Ex vivo graft purging and expansion of autologous blood progenitor cell products from patients with multiple myeloma
    Hong Yang
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Cancer Res 71:5040-9. 2011
    ....
  24. ncbi request reprint Reduced-intensity conditioning for unrelated donor hematopoietic stem cell transplantation as treatment for myeloid malignancies in patients older than 55 years
    Raymond Wong
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Blood 102:3052-9. 2003
    ..Unrelated donor transplantation is a treatment option for older patients with myeloid malignancies. The results in this cohort of patients are comparable with those reported in younger patients with similarly advanced disease...
  25. ncbi request reprint The role of alemtuzumab in nonmyeloablative hematopoietic transplantation
    Sergio Giralt
    University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 33:S36-43. 2006
    ....
  26. pmc NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT:
    Jeffrey S Miller
    Blood and Marrow Transplant Program, University of Minnesota, Minneapolis, Minnesota, USA
    Biol Blood Marrow Transplant 16:565-86. 2010
    ..Optimal strategies to precisely balance immune responses to favor GVL without harmful graft-versus-host disease (GVHD) are needed to protect against relapse, treat persistent disease and improve disease-free survival after HSCT...
  27. ncbi request reprint Treatment of relapsing refractory diffuse large cell lymphoma after matched unrelated donor bone marrow transplant with immunosuppression withdrawal and rituximab
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 4009, USA
    Leuk Lymphoma 44:829-32. 2003
    ..Lymphoma relapse occurred 4 months post-transplant. Immunosuppression withdrawal plus rituximab induced a complete response. He remains in complete remission (CR) 11 months post-immunosuppression withdrawal and 15 months post-transplant...
  28. doi request reprint Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemia
    Paul M Armistead
    Department of Stem Cell Transplantation and Cellular Therapy, MD Anderson Cancer Center, Houston Texas, USA
    Biol Blood Marrow Transplant 15:1431-8. 2009
    ..Our data suggest that HSCT is preferable to chemotherapy alone in these patients with poor prognoses, with particular benefits noted in patients under age 50 years...
  29. ncbi request reprint Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplantation: donor type matters
    Maha El-Zimaity
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Blood 103:4674-80. 2004
    ..We concluded that HC is more prevalent in MUD and UCB transplantations...
  30. pmc Hemorrhagic cystitis after allogeneic hematopoietic stem cell transplants is the complex result of BK virus infection, preparative regimen intensity and donor type
    Leandro De Padua Silva
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, Texas 77030, USA
    Haematologica 95:1183-90. 2010
    ..We hypothesized that patients with positive BK viruria before unrelated or mismatched related donor allogeneic hematopoietic stem cell transplantation have a higher incidence of hemorrhagic cystitis...
  31. doi request reprint Resolved hepatitis B virus infection is not associated with worse outcome after allogeneic hematopoietic stem cell transplantation
    Carlos A Ramos
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Biol Blood Marrow Transplant 16:686-94. 2010
    ..Our data suggest that seropositivity for HBcAb and seronegativity for HBsAg at the time of transplantation does not seem to adversely affect outcome after allo-HSCT...
  32. ncbi request reprint Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis
    Martin Korbling
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Transfusion 46:1795-802. 2006
    ..This study provides clinical data on the availability of circulating EPCs at steady state and after recombinant human granulocyte-colony-stimulating factor (rHuG-CSF) mobilization and their collection by leukapheresis...
  33. doi request reprint Complete remission of psoriasis after autologous hematopoietic stem-cell transplantation for multiple myeloma
    Fadi Braiteh
    Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Graduate School of Biomedical Sciences, University of Texas, Houston, TX, USA
    J Clin Oncol 26:4511-3. 2008
  34. pmc Scleromyxedema: role of high-dose melphalan with autologous stem cell transplantation
    Michele L Donato
    Department of Blood and Bone Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 107:463-6. 2006
    ..High-dose melphalan followed by autologous transplantation appears effective for improving the symptoms and systemic manifestations of scleromyxedema...
  35. doi request reprint Allogeneic stem cell transplantation for myelofibrosis with leukemic transformation
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX, USA
    Biol Blood Marrow Transplant 16:555-9. 2010
    ..Although limited by a small number of patients, this study suggests that patients with myelofibrosis and LT may achieve long-term remission after induction chemotherapy and ASCT...
  36. doi request reprint Donor-recipient mismatches in MHC class I chain-related gene A in unrelated donor transplantation lead to increased incidence of acute graft-versus-host disease
    Simrit Parmar
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 114:2884-7. 2009
    ..05). We conclude that MICA may represent novel a transplantation antigen recognized by human allogeneic T cells. This study was registered at ClinicalTrials.gov (Identifier NCT00506922)...
  37. ncbi request reprint Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma
    Athanasios Anagnostopoulos
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 100:2607-12. 2004
    ..In the current study, the authors compared the outcomes associated with high-dose melphalan (HDM) and a more intensive regimen of thiotepa, busulfan, and cyclophosphamide (TBC) in patients with multiple myeloma...
  38. pmc Effect of age on outcome of reduced-intensity hematopoietic cell transplantation for older patients with acute myeloid leukemia in first complete remission or with myelodysplastic syndrome
    Brian L McClune
    DO, University of Minnesota, Division of Hematology, Oncology and Transplantation, University of Minnesota, MMC 480, 420 Delaware St SE, Minneapolis, MN 55455, USA
    J Clin Oncol 28:1878-87. 2010
    ..Better pre-HCT performance status predicted improved 2-year OS. CONCLUSION With these similar outcomes observed in older patients, we conclude that older age alone should not be considered a contraindication to HCT...
  39. ncbi request reprint Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure
    Elias Jabbour
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 108:1421-3. 2006
    ..Seven patients are alive (6 in CMR) for a median of 19 months. Allo-SCT remains an important salvage option for patients who develop resistance to imatinib through Bcr-Abl mutations...
  40. ncbi request reprint Nonablative stem cell transplantation for older patients with acute leukemias and myelodysplastic syndromes
    Sergio Giralt
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Hematol 39:57-62. 2002
    ..Therefore strategies aimed at improving the safety and tolerability of allografting to allow for its more frequent application in older patients are necessary...
  41. ncbi request reprint Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation
    Maricer P Escalon
    Department of Blood and Marrow Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 22:2419-23. 2004
    ..We investigated the safety and efficacy of nonmyeloablative stem-cell transplantation in these patients...
  42. ncbi request reprint Stem cell transplantation for multiple myeloma: current status and future directions
    Humberto Caldera
    Department of Blood and Marrow Transplantation, University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Curr Hematol Rep 3:249-56. 2004
    ..In this review, the issues of who benefits from transplant, what is the optimal procedure, and whether there is a potential role for allografting are addressed...
  43. ncbi request reprint Nonmyeloablative reduced-intensity transplantation in multiple myeloma
    Athanasios Anagnastopoulos
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Semin Oncol 31:33-6. 2004
    ..New combinations and novel therapies need to be explored to improve outcomes. This strategy should also be employed earlier in the course of the disease...
  44. ncbi request reprint Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors
    Naoto T Ueno
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 448, Houston, TX 77030, USA
    Blood 102:3829-36. 2003
    ..It induces rapid complete donor chimerism without the need for donor lymphocyte infusion. Tumor regression associated with GVHD is consistent with graft-versus-tumor effect...
  45. pmc Serum interleukin-6 predicts the development of multiple symptoms at nadir of allogeneic hematopoietic stem cell transplantation
    Xin Shelley Wang
    Department of Symptom Research, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 113:2102-9. 2008
    ..However, the mechanism underlying the development of multiple symptoms has not been established...
  46. ncbi request reprint Autologous peripheral stem cell transplant for POEMS syndrome: a case report
    Sachin Gupta
    Department of Internal Medicine, University of Texas Health Science Center, Houston, USA
    Hematology 11:361-3. 2006
    ..A review of the literature is also presented. High-dose chemotherapy followed by stem cell transplantation is a potential treatment option for patients with POEMS syndrome...
  47. ncbi request reprint Is reduced-intensity conditioning the standard of care in the transplant setting?
    Sergio A Giralt
    Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Adv Hematol Oncol 6:337-9. 2008
  48. ncbi request reprint Adult Henoch-schönlein purpura in a patient with myelodysplastic syndrome and a history of follicular lymphoma
    Matthew C Fox
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Cutis 81:131-7. 2008
    ..We review cases of adult HSP associated with malignancy in the literature...
  49. doi request reprint Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin's lymphoma: the updated M.D. Anderson Cancer Center experience
    Paolo Anderlini
    The U T M D Anderson Cancer Center, Department of Stem Cell Transplantation and Cellular Therapy 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030 USA
    Haematologica 93:257-64. 2008
    ..We here present an update of our single-center experience with fludarabine-melphalan as a preparative regimen...
  50. ncbi request reprint Use of thrombopoietin in combination with chemotherapy and granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization
    James L Gajewski
    University of Texas M D Anderson Cancer Center, Department of Blood and Marrow Transplantation, Houston 77030 4095, USA
    Biol Blood Marrow Transplant 8:550-6. 2002
    ..Further studies are also warranted in patients who are likely to experience suboptimal PBPC mobilization when treated with currently available techniques...
  51. ncbi request reprint Clinical factors associated with cancer-related fatigue in patients being treated for leukemia and non-Hodgkin's lymphoma
    Xin Shelley Wang
    Department of Symptom Research, Division of Anesthesiology and Critical Care, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 20:1319-28. 2002
    ..To describe fatigue severity, fatigue interference, and associated factors in hematologic malignancies...
  52. ncbi request reprint Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia
    Hagop M Kantarjian
    Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston 77030, USA
    Blood 100:1590-5. 2002
    ..We conclude that imatinib mesylate effectively controlled CML that recurred after allogeneic SCT, but it was associated with side effects including myelosuppression and recurrence of severe GVHD...
  53. doi request reprint Arsenic trioxide with ascorbic acid and high-dose melphalan: results of a phase II randomized trial
    Muzaffar H Qazilbash
    Department of Stem Cell Transplantation and Cellular Therapy, UT M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:1401-7. 2008
    ..Addition of ATO + AA to high-dose melphalan is safe and well tolerated as a preparative regimen for MM...
  54. doi request reprint Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome: a dose and schedule finding study
    Marcos de Lima
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 116:5420-31. 2010
    ..The authors hypothesized that low-dose azacitidine administered after transplant would reduce recurrence rates, and conducted a study to determine a safe dose/schedule combination...
  55. ncbi request reprint Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy
    Issa Khouri
    M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 65, Houston, TX 77030 4095, USA
    Cancer Treat Res 110:137-47. 2002
  56. ncbi request reprint Nonablative versus reduced-intensity conditioning regimens in the treatment of acute myeloid leukemia and high-risk myelodysplastic syndrome: dose is relevant for long-term disease control after allogeneic hematopoietic stem cell transplantation
    Marcos de Lima
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:865-72. 2004
    ..Survival was improved for patients in CR at transplantation. In conclusion, FM provided better disease control though at a cost of increased TRM and morbidity...
  57. doi request reprint Poor hematopoietic stem cell mobilizers: a single institution study of incidence and risk factors in patients with recurrent or relapsed lymphoma
    Chitra Hosing
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Am J Hematol 84:335-7. 2009
    ..In the subset of patients who undergo chemomobilization for non-Hodgkin's lymphoma platelet count at the time of mobilization is a predictor of mobilization failure...
  58. ncbi request reprint Double-chimaerism after transplantation of two human leucocyte antigen mismatched, unrelated cord blood units
    Marcos de Lima
    Department of Blood and Marrow Transplantation, Pathology, and Leukaemia, M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 119:773-6. 2002
    ..Triple chimaerism was present from relapse until death due to leukaemia. This approach may potentially improve UCB transplantation outcome for adults lacking a histocompatible donor...
  59. ncbi request reprint Allogeneic transplantation for the elderly patient with acute myelogenous leukemia or myelodysplastic syndrome
    Marcos de Lima
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, TX 77033, USA
    Semin Hematol 43:107-17. 2006
    ..Here we review current results of allogeneic blood and marrow transplantation for AML and MDS in the elderly...
  60. ncbi request reprint Long-term follow-up of a phase I study of high-dose decitabine, busulfan, and cyclophosphamide plus allogeneic transplantation for the treatment of patients with leukemias
    Marcos de Lima
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030 4095, USA
    Cancer 97:1242-7. 2003
    ..Decitabine is a hypomethylating agent that has activity in patients with leukemia. The authors combined decitabine with busulfan and cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic stem cell transplantation...
  61. ncbi request reprint Nonmyeloablative preparative regimens for allogeneic hematopoietic transplantation. Biology and current indications
    Richard Champlin
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, Texas, USA
    Oncology (Williston Park) 17:94-100; discussion 103-7. 2003
    ....
  62. ncbi request reprint 166Ho-DOTMP plus melphalan followed by peripheral blood stem cell transplantation in patients with multiple myeloma: results of two phase 1/2 trials
    Sergio Giralt
    The University of Texas, MD Anderson Cancer Center, Houston, TX 77030 4006, USA
    Blood 102:2684-91. 2003
    ..With a minimum follow-up of 23 months, the median survival had not been reached and the median event-free survival was 22 months. 166Ho-DOTMP is a promising therapy for patients with multiple myeloma and merits further evaluation...
  63. doi request reprint Nonmyeloablative allogeneic stem cell transplantation for chronic myelogenous leukemia in the imatinib era
    Richard Champlin
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma Myeloma 9:S261-5. 2009
    ..This approach, including posttransplantation treatment with TKIs and donor lymphocyte infusion, produces a high fraction of durable molecular complete remissions...
  64. ncbi request reprint Acute and chronic graft-versus-host disease after ablative and nonmyeloablative conditioning for allogeneic hematopoietic transplantation
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77030 4095, USA
    Biol Blood Marrow Transplant 10:178-85. 2004
    ..It is interesting to note that nonrelapse mortality with nonmyeloablative regimens in older and more debilitated patients was low (14%) and comparable to that achieved with standard high-dose regimens in younger patients...
  65. pmc Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study
    Simrit Parmar
    Department of Stem Cell Transplantation and Cell Therapy, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    J Clin Oncol 29:294-302. 2011
    ....
  66. ncbi request reprint Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS
    Marcos de Lima
    Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:857-64. 2004
    ..The results suggest that intravenous busulfan-fludarabine is an efficacious, reduced-toxicity, myeloablative-conditioning regimen for patients with AML or MDS undergoing HSCT...
  67. doi request reprint Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma
    Uday Popat
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 15:718-23. 2009
    ..In patients with multiple myeloma, prior lenalidomide therapy is associated with failure of stem cell mobilization with filgrastim. Remobilization with chemotherapy and filgrastim is usually successful in these patients...
  68. ncbi request reprint Tumor necrosis factor-alpha blockade for the treatment of acute GVHD
    Daniel Couriel
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Blood 104:649-54. 2004
    ..Survival after steroid-resistant acute GVHD continues to be problematic. The possibility of excessive fungal and other infections must be explored further...
  69. doi request reprint Long-term follow-up of patients who experienced graft failure postallogeneic progenitor cell transplantation. Results of a single institution analysis
    Gabriela Rondon
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Biol Blood Marrow Transplant 14:859-66. 2008
    ..Collection of autologous stem cells prior to high-risk allografting can salvage a fraction of patients and lead to prolonged survivals...
  70. ncbi request reprint Hematopoietic progenitor cell transplantation in 2007: new challenges and new opportunities for the center for international blood and marrow transplant research
    Sergio Giralt
    University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 13:263-4. 2007
  71. ncbi request reprint High-dose rituximab does not negatively affect peripheral blood stem cell mobilization kinetics in patients with intermediate-grade non-Hodgkin's lymphoma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas, MD Anderson Cancer Center, Houston, TX 77030, USA
    Leuk Lymphoma 47:1290-4. 2006
    ..In conclusion, high-dose rituximab given during stem cell mobilization does not negatively affect stem cell mobilization kinetics...
  72. ncbi request reprint Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma
    Chitra Hosing
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Br J Haematol 133:533-7. 2006
    ..A single fixed dose of pegfilgrastim was effective in mobilising adequate peripheral blood progenitor cells in patients with multiple myeloma. The efficacy and toxicity profile was similar to that described with filgrastim treatment...
  73. ncbi request reprint Extracorporeal photochemotherapy for the treatment of steroid-resistant chronic GVHD
    Daniel R Couriel
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030, USA
    Blood 107:3074-80. 2006
    ..Objective responses were observed in a substantial number of patients with both skin and visceral chronic GVHD failing corticosteroids and other immunosuppression...
  74. ncbi request reprint Transplant-associated microangiopathy in patients receiving tacrolimus following allogeneic stem cell transplantation: risk factors and response to treatment
    Betul Oran
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 13:469-77. 2007
    ..Control of TAM generally requires response of associated infections and GVHD. TMA response may occur despite continuation of tacrolimus treatment...
  75. ncbi request reprint Normal hematopoietic function and multiple bone marrow clonal abnormalities in a patient with acute myeloid leukemia after two mismatched stem-cell transplants with graft failure and autologous reconstitution
    Fabiana Ostronoff
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Am J Hematol 82:744-7. 2007
    ....
  76. ncbi request reprint Prospective feasibility analysis of reduced-intensity conditioning (RIC) regimens for hematopoietic stem cell transplantation (HSCT) in elderly patients with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MDS)
    Elihu Estey
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 109:1395-400. 2007
    ..99 (P=.004). Results were similar with respect to survival. While RIC-HSCT thus seems of interest, methods are needed to extend its applicability...
  77. ncbi request reprint Graft-versus-leukaemia effect after non-myeloablative haematopoietic transplantation can overcome the unfavourable expression of ZAP-70 in refractory chronic lymphocytic leukaemia
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Br J Haematol 137:355-63. 2007
    ..These results demonstrate a potent graft-versus-leukaemia effect that can overcome the adverse prognostic effect of ZAP-70 expression...
  78. doi request reprint Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab
    Issa F Khouri
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 111:5530-6. 2008
    ..Only 5 patients were still undergoing immunosuppressive therapy at the time of last follow-up. We believe that the described results are a step forward toward developing a curative strategy for recurrent follicular lymphoma...
  79. ncbi request reprint Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation
    Dimitrios P Kontoyiannis
    Department of Infectious Diseases, Infection Control, and Employee Health, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 110:1303-6. 2007
    ..Laboratory studies have demonstrated that iron is essential for Aspergillus growth and virulence...
  80. ncbi request reprint Long-term follow-up of allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning for patients with chronic myeloid leukemia
    Partow Kebriaei
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 110:3456-62. 2007
    ..TRM rates are acceptable in this high-risk population but increase over time...
  81. ncbi request reprint High-dose topotecan, melphalan and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of multiple myeloma
    Michele L Donato
    Department of Blood and Marrow Transplantation, The University of Texas M D Anderson Cancer Center, Houston 77030 4095, USA
    Leuk Lymphoma 45:755-9. 2004
    ..With a median follow up of 12.3 months, 89% of patients are alive. The TMC regimen is well tolerated and produces high response rates. Further evaluation of TMC to fully assess response and survival is ongoing...
  82. doi request reprint Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS
    Borje S Andersson
    Department of Stem Cell Transplantation and Cellular Therapy, U T M D Anderson Cancer Center, 1515 Holcombe Blvd, Unit 423, Houston, TX 77030 4009, USA
    Biol Blood Marrow Transplant 14:672-84. 2008
    ..These results support replacing BuCy +/- ATG with Bu-Flu +/- rabbit-antithymocyte globulin (ATG), and warrant a prospective comparison between allogeneic HSCT and conventional induction/consolidation chemotherapy for AML in CR1...
  83. ncbi request reprint Rituximab-induced acute liver failure after an allogeneic transplantation for chronic myeloid leukemia
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, UT MD Anderson Cancer Center, Houston, 77030, USA
    Am J Hematol 80:43-5. 2005
    ..The patient developed autoimmune hemolytic anemia that failed to respond to steroids, intravenous immunoglobulins, and plasma exchange. She was then treated with rituximab that resulted in fatal acute liver toxicity...
  84. ncbi request reprint Nonmyeloablative stem cell transplantation for chronic myeloid leukemia
    Muzaffar H Qazilbash
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 423, Houston, TX 77030, USA
    Hematol Oncol Clin North Am 18:703-13, xi. 2004
    ..The development of nonmyeloablative transplantation has allowed the application of a potentially curative procedure to elderly or medically infirm patients who would not be able to tolerate high-dose conditioning regimens...
  85. ncbi request reprint Allogeneic hematopoietic progenitor cell transplantation for the treatment of chronic myelogenous leukemia in the era of tyrosine kinase inhibitors: lessons learned to date
    Sergio Giralt
    Department of Stem Cell Transplantation and Cellular Therapies University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA E mail
    Clin Lymphoma Myeloma 7:S102-4. 2007
    ..In this article, we will address the role of allogeneic transplantation in the context of imatinib and other tyrosine kinase inhibitors...
  86. ncbi request reprint Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival
    Issa F Khouri
    Department of Blood and Marrow Transplantation, M D Anderson Cancer Center, Houston, Tex 77030, USA
    Exp Hematol 32:28-35. 2004
    ..To investigate the graft-vs-leukemia effect of allogeneic stem cell transplantation after a nonablative conditioning regimen as treatment for patients with chronic lymphocytic leukemia...
  87. ncbi request reprint Hyperacute GVHD: risk factors, outcomes, and clinical implications
    Rima M Saliba
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, Houston 77030, USA
    Blood 109:2751-8. 2007
    ..In conclusion, hyperacute GVHD accounts for a substantial proportion of grade II-IV acute GVHD after HSCT. Patients at high risk or with a diagnosis of hyperacute GVHD should be included in clinical studies...
  88. pmc Impact of hepatitis C virus seropositivity on survival after allogeneic hematopoietic stem cell transplantation for hematologic malignancies
    Carlos A Ramos
    Department of Stem Cell, Transplantation and Cellular Therapy, The University of Texas M D, Anderson Cancer Center 1515 Holcombe Blvd, Unit 423, Houston, TX 77030, USA
    Haematologica 94:249-57. 2009
    ....
  89. ncbi request reprint Prognostic factors for outcomes of patients with refractory or relapsed acute myelogenous leukemia or myelodysplastic syndromes undergoing allogeneic progenitor cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA
    Biol Blood Marrow Transplant 11:108-14. 2005
    ....
  90. doi request reprint Aging, acute myelogenous leukemia, and allogeneic transplantation: do they belong in the same sentence?
    Stefan O Ciurea
    Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M D Anderson Cancer Center, Houston, TX 77033, USA
    Clin Lymphoma Myeloma 9:289-97. 2009
    ..Herein, we review the current literature on transplantation for older patients with this myeloid malignancy...
  91. doi request reprint The outcome of IgD myeloma after autologous hematopoietic stem cell transplantation is similar to other Ig subtypes
    Manish Sharma
    Department of Stem Cell Transplantation and Cellular Therapy, University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Am J Hematol 85:502-4. 2010
    ..Median PFS and OS were 18 and 45 months, respectively. These results were comparable with patients receiving autologous HCT for other Ig subtypes of myeloma...
  92. doi request reprint Reducing the toxicity of cancer therapy: recognizing needs, taking action
    Charles S Cleeland
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1450, Houston, TX 77030, USA
    Nat Rev Clin Oncol 9:471-8. 2012
    ..With an emphasis on coordinating multidisciplinary efforts, this panel has presented a strategy to increase funding for the field and develop a coherent research agenda...
  93. pmc Changes in pain and other symptoms in patients with painful multiple myeloma-related vertebral fracture treated with kyphoplasty or vertebroplasty
    Tito R Mendoza
    Department of Symptom Research, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Pain 13:564-70. 2012
    ....
  94. doi request reprint Outcomes in patients with relapsed or refractory acute promyelocytic leukemia treated with or without autologous or allogeneic hematopoietic stem cell transplantation
    Naveen Pemmaraju
    Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Clin Lymphoma Myeloma Leuk 13:485-92. 2013
    ..Outcomes in patients with acute promyelocytic leukemia (APL) have improved; however, a significant number of patients still relapse despite receiving all-trans-retinoic acid (ATRA) and arsenic-based therapies...
  95. pmc Evaluating quality in clinical cancer research: the M.D. Anderson Cancer Center experience
    James D Cox
    Division of Radiation Oncology, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Oncology 77:75-81. 2009
    ....
  96. ncbi request reprint Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation
    Raymond Wong
    Department of Blood and Marrow Transplantation, MD Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
    Br J Haematol 122:128-34. 2003
    ..One patient was changed to cyclosporine. In most patients, subsequent treatment with tacrolimus was well tolerated without recurrence of neurotoxicity...
  97. ncbi request reprint Multiphasic CT and MRI appearances of extramedullary multiple myeloma involving the stomach, pancreas, and bladder
    Toshiki Kazama
    Department of Diagnostic Radiology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030 4009, USA
    Clin Imaging 29:263-5. 2005
    ..The stomach and pancreatic lesions were demonstrated as hypervascular nodules on computed tomography (CT), more conspicuous on arterial phase images. Early phase post-contrast imaging might improve the detection of extraosseous myeloma...
  98. ncbi request reprint Low prevalence of premature ovarian failure in women given reduced-intensity conditioning regimens for hematopoietic stem-cell transplantation
    Yee Chung Cheng
    Haematologica 90:1725-6. 2005
    ..5%) than among those given high-dose conditioning regimens (79%) for hematopoietic stem-cell transplantation (p=0.007)...
  99. ncbi request reprint Validation and extension of the EBMT Risk Score for patients with chronic myeloid leukaemia (CML) receiving allogeneic haematopoietic stem cell transplants
    Jakob R Passweg
    Kantonsspital Basel, Basel, Switzerland
    Br J Haematol 125:613-20. 2004
    ..Sokal and Hasford Scores did not predict survival after HSCT. We concluded that the EBMT Risk Score does not currently require modification...
  100. pmc Comparison of twin and autologous transplants for multiple myeloma
    Asad Bashey
    BMT Group of Georgia, Atlanta, GA, USA
    Biol Blood Marrow Transplant 14:1118-24. 2008
    ..49, 95% confidence interval [CI] 0.28-0.86, P = .011). Twin transplants have a significantly lower relapse risk than autotransplants in MM, suggesting that graft composition may impact outcomes following high-dose chemotherapy...
  101. ncbi request reprint Autologous transplantation for diffuse aggressive non-Hodgkin lymphoma in first relapse or second remission
    Julie M Vose
    University of Nebraska Medical Center, Omaha 68198 7680, USA
    Biol Blood Marrow Transplant 10:116-27. 2004
    ..Exposure to myeloid growth factors to accelerate recovery for recipients of bone marrow grafts may increase the risk of disease progression or death...

Research Grants2

  1. Blood Marrow Transplant Clinical Trials Research Network
    Sergio Giralt; Fiscal Year: 2007
    ..End of abstract.) ..